0 2 I N C O M E S T A T E M E N T A N D B A L A N C E S H E E T
0 3 2 0 2 2 O U T L O O K
0 4 R J F S H A R E P E R F O R M A N C E
Q3 2022
R E S U L T S
01
RESULTS FROM THIRD QUARTER OF 2022
REIG JOFRE had 13% growth in revenue and 6% growth in EBITDA at the end of September 2022
SALES
+ 13%
€195.3 million
EBITDA
+ 6%
€21.2 million
CONSOLIDATED - 16%
REVENUE
€4.3 million
The cumulative sales figure in the third quarter of 2022 reached €195 million, exceeding the same period in 2021 by 13%. The growth in pharmaceutical technology products, the start of manufacture and sales in the new injection plant in Barcelona and good performance in the Forté Pharma food supplement ranges are the main drivers of this growth.
The largest growth is reflected in sales in the domestic market, a growth of 13%, and in the rest of Europe, which has reached a 17% growth in revenues, driven by the countries in which Reig Jofre is present with its own companies and specialised sales networks: France, Belgium, UK, Poland and Sweden and the Nordic countries.
The Consumer Healthcare unit shows the highest growth, 19%, and the Pharmaceutical Technologies unit has consolidated a 15% growth, following a lower demand for these products in 2021.
In September 2022, the Group's EBITDA reached €21.2 million, a 6% increase over the same period of the previous year.
The higher depreciation due to investments in technology, as well as higher financial expense have had an impact on the quarter's consolidated result, which stands at €4.3 million, representing a decline compared to 2021.
As for the €5.4 million industrial investments made, they correspond to technological improvements in the Toledo and Barcelona plants and to the construction of a new manufacturing line in Sweden dedicated to the development and production of the group's dermatological products.
4
REVENUES BY BUSINESS UNIT
PHARMACEUTICAL
TECHNOLOGIES
Antibiotics
Injectables/Lyophilisates
45%
87,6
m i l l i o n €
+15%
The hospital product unit grew by 15%, in a context of antibiotic consumption recovery, after the social distancing measures ended.
The new injectables plant in Barcelona has increased the level of activity with its own products and CMO manufacturing projects.
Sales in European markets have grown by 26%. Spain grew by 15% while the rest of the world had a 3% drop.
International Sales
PHARMACEUTICAL 61%
TECHNOLOGIESInternational
SPECIALITY
PHARMACARE
Osteoarticular
Dermatology
29%
56,6
m i l l i o n €
+5%
The prescription product unit, which already achieved a growth of 14% in 2021 in a market in clear recovery, managed to grow by 5% in revenue in 2022.
The new launches in the dermatological unit and the consolidation of commercial networks in Europe should enable this trend to continue.
Geographically, the greatest growth can be seen in the UK and, especially, in Poland where Reig Jofre created its subsidiary in 2021. Both countries have their own commercial networks.
SPECIALITY
PHARMACARE28%
International
CONSUMER
HEALTHCARE
OTC Energy
Stress and sleep
Weight management
Beauty
51,1
26%
m i l l i o n €
+19%
The Consumer Healthcare unit consolidated the trend, growing over 20% in Spain and 18% in other European countries with France taking the lead.
The Forté Pharma brand of Food Supplements accounts for 70% of the revenue and continues to grow in France, Belgium and Spain and in the rest of the world, specially in its online channels.
OTC products in the respiratory and ENT product ranges also grew by 18%, a trend that began in 2021.
CONSUMER
HEALTHCARE75%
International 5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Laboratorio Reig Jofre SA published this content on 28 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2022 07:02:04 UTC.
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
LABORATORIO REIG JOFRE, S.A. 
